- Dasatinib Hydrate
- 商品名:スプリセル錠(ブリストル・マイヤーズ スクイブ株式会社)
- 血漿中濃度に対する血液濃度比(C 血液/C 血漿)は 1.8 (承認審査概要 2.7.1 生物薬剤学及び関連する分析法の概要 p.79)
- 分布容積(Vz)は 141〜1010 L (承認審査概要 2.7.1 生物薬剤学及び関連する分析法の概要 p.79)
- 総放射能に対して 13%以上の割合で存在する代謝物は認められなかった(承認審査概要 2.7.1 生物薬剤学及び関連する分析法の概要 p.80)
- 代謝酵素:CYP3A4 、フラビン含有モノオキシゲナーゼ酵素(FMO3)(承認審査概要 2.7.1 生物薬剤学及び関連する分析法の概要 p.80)
- (2.7.2 臨床薬理の概要 p.62)
V2/F = θ2×EXP(η2)
Q/F = θ3
V3/F = θ4
KA = θ1/θ2×{1+1/[θ5×EXP(η3)]}
F = EXP(ηiov)
- HB =血中ヘモグロビン[g/dL]
パラメータ / 記号 | 推定値 | 標準誤差 | (RSE%) 95%信頼区間 |
CLint/F (L/h) θ1 | 314 | 10.4 (3.31) | 294 - 334 |
V2/F (L) θ2 | 1250 | 73.9 (5.91) | 1110 - 1390 |
Q/F (L/h) θ3 | 130 | 12.1 (9.31) | 106 - 154 |
V3/F (L) θ4 | 1320 | 134 (10.2) | 1060 - 1580 |
Ka1 θ5 | 0.167 | 0.0230 (13.8) | 0.122 - 0.212 |
CLHB/F (L/h) θ6 | -12.4 | 2.24 (18.1) | -16.8 - -8.01 |
パラメータ / 記号 | 推定値 | 標準誤差 | (RSE%) 95%信頼区間 |
IIV_CL/F ω1,1 | 0.103 (0.321) | 0.0240 (23.3) | 0.0560 - 0.150 |
IIV_V2/F ω2,2 | 0.694 (0.833) | 0.115 (16.6) | 0.469 - 0.919 |
IIV_Ka d ω3,3 | 1.00 に固定 | -- | -- |
IOVF ω4,4 | 0.260 (0.510) | 0.0344 (13.2) | 0.193 - 0.327 |
IIV_CL/F: | |||
IIV_V2/F ω1,2 | 0.243(0.909) | 0.0476 (19.6) | 0.150 - 0.336 |
- Clin Cancer Res. 2006 Dec 1;12(23):7180-6.
- Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
- PMID: 17145844 https://www.ncbi.nlm.nih.gov/pubmed/17145844
- Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.
- Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
- PMID: 17429625 https://www.ncbi.nlm.nih.gov/pubmed/17429625
- Cancer. 2010 Mar 15;116(6):1582-91. doi: 10.1002/cncr.24927.
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
- PMID: 20108303 https://www.ncbi.nlm.nih.gov/pubmed/20108303
- Cancer Sci. 2011 Nov;102(11):2058-64. doi: 10.1111/j.1349-7006.2011.02041.x. Epub 2011 Sep 1.
- Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
- PMID: 21781226 https://www.ncbi.nlm.nih.gov/pubmed/21781226
- Cancer Chemother Pharmacol. 2012 Aug;70(2):351-2. doi: 10.1007/s00280-012-1900-4. Epub 2012 Jun 8.
- H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.
- PMID: 22678358 https://www.ncbi.nlm.nih.gov/pubmed/22678358
- J Hematol Oncol. 2012 May 15;5:23. doi: 10.1186/1756-8722-5-23.
- Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
- PMID: 22587422 https://www.ncbi.nlm.nih.gov/pubmed/22587422
- J Neurooncol. 2012 Jul;108(3):499-506. doi: 10.1007/s11060-012-0848-x. Epub 2012 Mar 10.
- Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
- PMID: 22407177 https://www.ncbi.nlm.nih.gov/pubmed/22407177
- Cancer Chemother Pharmacol. 2012 Apr;69(4):999-1004. doi: 10.1007/s00280-011-1797-3. Epub 2011 Dec 7.
- Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
- PMID: 22147077 https://www.ncbi.nlm.nih.gov/pubmed/22147077
- Invest New Drugs. 2012 Aug;30(4):1575-84. doi: 10.1007/s10637-011-9732-3. Epub 2011 Sep 1.
- Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
- PMID: 21881918 https://www.ncbi.nlm.nih.gov/pubmed/21881918
- Clin Cancer Res. 2012 Oct 1;18(19):5489-98. doi: 10.1158/1078-0432.CCR-12-0507. Epub 2012 Jul 26.
- A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
- PMID: 22837181 https://www.ncbi.nlm.nih.gov/pubmed/22837181
- Clin Cancer Res. 2013 Jun 1;19(11):3050-8. doi: 10.1158/1078-0432.CCR-13-0306. Epub 2013 Mar 27.
- Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
- PMID: 23536435 https://www.ncbi.nlm.nih.gov/pubmed/23536435
- Leuk Lymphoma. 2013 Jul;54(7):1557-9. doi: 10.3109/10428194.2012.745933. Epub 2012 Dec 22.
- Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
- PMID: 23194002 https://www.ncbi.nlm.nih.gov/pubmed/23194002
- Eur J Clin Pharmacol. 2016 Feb;72(2):185-93. doi: 10.1007/s00228-015-1968-y. Epub 2015 Oct 27.
- Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
- PMID: 26507546 https://www.ncbi.nlm.nih.gov/pubmed/26507546
コメントをかく